Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer
Transanal Versus Laparoscopic Total Mesorectal Excision for Mid and Low Rectal Cancer (TaLaR): a Multicentre Randomised Clinical Trial
Sun Yat-sen University
1,114 participants
Apr 1, 2016
INTERVENTIONAL
Conditions
Summary
Laparoscopic surgery for rectal cancer has been successfully proven to be a non-inferior alternative regarding resection quality, and oncological outcomes of patients as compared to open surgery in mangy clinical trails. Moreover, laparoscopic surgery is advantageous over open surgery with regard to operative invasiveness, patient's recovery, and wound related complications. Thus, laparoscopic surgery has gained great popularity over the past decades. However, specifically for mid and low rectal cancer, laparoscopic surgery is technically demanding, which sometimes leads to high morbidity and unsatisfactory resection quality, especially in challenging cases such as bulky mesorectum, enlarged prostate, irradiated pelvis, etc. Under this circumstance, transanal total mesorectal excision (TaTME) , the so called "down-to-up" alternative, has emerged as a promising solution to these problems in recent years and more and more small studies have proven the feasibility and advantages of this technique, making it become a hot topic among both literature and conferences. However, TaTME is still at early birth, higher-level evidences, either multicentric, or comparative study with conventional surgery is strikingly lacking. Thus the investigators conduct this multicentre randomised clinical trial, comparing transanal TME versus laparoscopic TME for mid and low rectal cancer, aiming to prove the hypothesis that TaTME may achieve better resection quality and result in non-inferior oncological outcome, as well as short term operative morbidity and mortality.
Eligibility
Inclusion Criteria9
- histologically proven rectal adenocarcinoma;
- tumor located below the level of peritoneal reflection ;
- diagnosis of rectal cancer amenable to curative surgery;
- no evidence of distant metastases;
- preoperative tumor stage within III;
- no threaten mesorectal fascia (MRF)after neoadjuvant therapy;
- no contraindication to laparoscopic surgery;
- without history of other malignancies;
- Written informed consent
Exclusion Criteria13
- could not perform sphincter preservation surgery (requiring a Mile's procedure);
- T4b tumor invading adjacent organs;
- T1 tumors that can be locally resected
- should take neoadjuvant therapy but refuse it;
- recurrent cancer;
- concurrent or previous diagnosis of invasive cancer within 5 years;
- emergent surgery with intestinal obstruction or perforation;
- history of colorectal surgery;
- fecal incontinence;
- history of inflammatory bowel disease;
- with contraindications to general anaesthesia(ASA class 4 or 5);
- pregnant or breast-feeding;
- history of mental disorder
Interventions
Transanal Total Mesorectal Excision
Conventional Laparoscopic Total Mesorectal Excision
Locations(16)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02966483